DDInter504 DDInter927
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Desipramine {u} (Compound) resembles {v} (Compound) Aprindine
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Desipramine {u} (Compound) binds {v} (Gene) SLC22A2
Desipramine {u} (Compound) upregulates {v} (Gene) ALDOC
Desipramine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Desipramine {u} (Compound) downregulates {v} (Gene) HAT1
Desipramine {u} (Compound) causes {v} (Side Effect) Disturbance in sexual arousal
Desipramine (Compound) resembles Aprindine (Compound)
Desipramine (Compound) resembles Protriptyline (Compound)
Desipramine (Compound) binds SLC22A2 (Gene)
Desipramine (Compound) upregulates ALDOC (Gene)
Desipramine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Desipramine (Compound) downregulates HAT1 (Gene)
Desipramine (Compound) causes Disturbance in sexual arousal (Side Effect)